Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146054 · ClinicalTrials.gov registry record · Phase 2
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01146054: Completed Phase 2 study, sponsored by Stanford University.
NCT01146054 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01146054, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DEVICE CyberKnife based stereotactic radiotherapy
- DRUG Fludeoxyglucose (18F) (FDG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146054
The ClinicalTrials.gov registry entry for NCT01146054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT01146054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01146054 about?
NCT01146054 is a clinical study titled "Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma". This multi-institutional trial aims to evaluate the potential benefit and side effects of adding fractionated stereotactic body radiotherapy/surgery (SBRT) before and after chemotherapy with gemcitabine for locally advanced pancreatic cancer.
What is the current status of trial NCT01146054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2009-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01146054?
The interventions under investigation include: Gemcitabine (DRUG), CyberKnife based stereotactic radiotherapy (DEVICE), Fludeoxyglucose (18F) (FDG) (DRUG).
Who is sponsoring clinical trial NCT01146054?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.